X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57) 57
male (47) 47
adult (45) 45
middle aged (38) 38
female (31) 31
index medicus (29) 29
infectious diseases (25) 25
aids (21) 21
hiv infections - drug therapy (20) 20
anti-hiv agents - therapeutic use (16) 16
immunology (16) 16
aged (15) 15
prospective studies (15) 15
virology (15) 15
hiv (14) 14
viral load (14) 14
treatment outcome (13) 13
antiretroviral therapy (12) 12
hiv infections - virology (12) 12
retrospective studies (12) 12
genotype (11) 11
young adult (11) 11
antiretroviral therapy, highly active (10) 10
cd4 lymphocyte count (10) 10
anti-hiv agents - adverse effects (9) 9
drug therapy, combination (9) 9
hepatitis c (9) 9
human-immunodeficiency-virus (9) 9
medicine & public health (9) 9
therapy (9) 9
efficacy (8) 8
follow-up studies (8) 8
gastroenterology and hepatology (8) 8
hiv infections - immunology (8) 8
interferon (8) 8
ribavirin (8) 8
risk factors (8) 8
safety (8) 8
clinical trials (7) 7
double-blind method (7) 7
gastroenterology & hepatology (7) 7
hepatitis c virus (7) 7
prognosis (7) 7
active antiretroviral therapy (6) 6
aids-related opportunistic infections - drug therapy (6) 6
cancer (6) 6
care and treatment (6) 6
drug therapy (6) 6
germany (6) 6
germany - epidemiology (6) 6
health aspects (6) 6
hepacivirus - genetics (6) 6
hepatitis c, chronic - drug therapy (6) 6
hiv infections - complications (6) 6
hiv-1 - drug effects (6) 6
infection (6) 6
infections (6) 6
patients (6) 6
research (6) 6
chemotherapy (5) 5
cohort studies (5) 5
combination (5) 5
disease (5) 5
drug administration schedule (5) 5
electricity (5) 5
genetic aspects (5) 5
hematology (5) 5
hepatitis (5) 5
hiv infection (5) 5
hiv-1 (5) 5
internal medicine (5) 5
kaposi's sarcoma (5) 5
medicine, general & internal (5) 5
physics (5) 5
resistance (5) 5
ribavirin - therapeutic use (5) 5
urology & nephrology (5) 5
adhesives (4) 4
aids/hiv (4) 4
analysis (4) 4
anti-hiv agents - administration & dosage (4) 4
antiviral agents - therapeutic use (4) 4
artificial stone (4) 4
basic electric elements (4) 4
cements (4) 4
ceramics (4) 4
chemistry (4) 4
compositions thereof, e.g. mortars, concrete or like buildingmaterials (4) 4
concrete (4) 4
dyes (4) 4
epidemiology (4) 4
further section (4) 4
gastroenterology (4) 4
general practice / family medicine (4) 4
genotypes (4) 4
hcv (4) 4
hepatitis c, chronic - virology (4) 4
infected patients (4) 4
interferon-alpha - therapeutic use (4) 4
lime, magnesia (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Cahn, Pedro and Madero, Juan Sierra and Arribas, José Ramón and Antinori, Andrea and Ortiz, Roberto and Clarke, Amanda E and Hung, Chien-Ching and Rockstroh, Jürgen K and Girard, Pierre-Marie and Sievers, Jörg and Man, Choy and Currie, Alexander and Underwood, Mark and Tenorio, Allan R and Pappa, Keith and Wynne, Brian and Fettiplace, Anna and Gartland, Martin and Aboud, Michael and Smith, Kimberly and Cassetti, Lidia and David, Daniel and Figueras, Laura and Losso, Marcelo and Lopardo, Gustavo and Lupo, Sergio and Porteiro, Norma and Sánchez, Marisa and Bloch, Mark and Cooper, David and Finlayson, Robert and Kelleher, Anthony and Koh, Kenneth and Lewis, David and McMahon, James and Moore, Richard and Roth, Norman and Shields, Matthew and De Wit, Stephane and Florence, Eric and Goffard, Jean-Christophe and Demeester, Remy and Lacor, Patrick and Vandercam, Bernard and Vandekerckhove, Linos and Angel, Jonathan and Baril, Jean-Guy and Conway, Brian and De Pokomandy, Alexandra and Szabo, Jason and Walmsley, Sharon and Bouchaud, Olivier and Chidiac, Christian and Delobel, Pierre and Goujard, Cecile and Katlama, Christine and Molina, Jean-Michel and Pialoux, Gilles and Philibert, Patrick and Bogner, Johannes and Esser, Stefan and Krznaric, Ivanka and Lehmann, Clara and Spinner, Christoph and Stellbrink, Hans-Jurgen and Stephan, Christoph and Stoehr, Albrecht and Barchi, Enrico and Caramello, Pietro and Castelli, Francesco and Cattelan, Anna Maria and D'Arminio Monforte, Antonella and Di Biagio, Antonio and Di Perri, Giovanni and Gori, Andrea and Maggiolo, Franco and Menzaghi, Barbara and Migliorino, Guglielmo and Mussini, Cristina and Penco, Giovanni and Puoti, Massimo and Rizzardini, Giuliano and Gulminetti, Roberto and Lazzarin, Adriano and Quirino, Tiziano and Sighinolfi, Laura and Viale, Pierluigi and Amaya Tapia, Gerardo and Andrade Villanueva, Jaime and Granados Reyes, Enrique R and Perez Rios, Alma and Santoscoy Gomez, Mario and Den Hollander, Jan and Rijnders, Bart and Hidalgo, José A and Hercilla Vasquez, Luis and Illescas, Luis and Olczak, Anita and Mansinho, Kamal and Correia Pacheco, Patricia Paula and ... and GEMINI Study Team
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Journal Article
PLOS ONE, ISSN 1932-6203, 04/2019, Volume 14, Issue 4, p. e0214795
Background Newer direct-acting antiviral therapies are increasingly becoming the therapy of choice in patients with hepatitis C virus (HCV) infection. Here, we... 
VELPATASVIR | VIRUS-INFECTION | EFFICACY | HCV GENOTYPE 1 | MULTIDISCIPLINARY SCIENCES | RIBAVIRIN | COMPENSATED CIRRHOSIS | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Young Adult | Benzimidazoles - administration & dosage | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Retrospective Studies | Uridine Monophosphate - adverse effects | Safety | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Carbamates - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Germany | Cohort Studies | Antiviral agents | Complications and side effects | Dosage and administration | Research | Hepatitis C | Drug therapy | Clinical trials | Viruses | Infections | Patients | Ribavirin | Subgroups | Hepatitis | Genotype & phenotype | Cirrhosis | Hepatology | Gastroenterology | Interferon | Hepatitis C virus | Genotypes
Journal Article
Journal of Hepatology, ISSN 0168-8278, 05/2019, Volume 70, Issue 5, pp. 1019 - 1023
Curative treatment of patients who previously failed hepatitis C virus (HCV) therapies is critical to achieving HCV elimination. Glecaprevir/pibrentasvir (G/P)... 
Resistance | Retreatment | G/P | HCV | RAS | SOFOSBUVIR | OPEN-LABEL | RIBAVIRIN | HCV INFECTION | GENOTYPE 1 | VELPATASVIR | PIBRENTASVIR | CLINICAL-TRIALS | RESISTANCE-ASSOCIATED SUBSTITUTIONS | GASTROENTEROLOGY & HEPATOLOGY | ANTIVIRAL DRUGS | Hepatitis C
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 04/2019, Volume 49, Issue 8, pp. 1052 - 1059
Summary Background Glecaprevir/pibrentasvir is a pangenotypic direct‐acting antiviral regimen approved for treating adults chronically infected with hepatitis... 
PHARMACOLOGY & PHARMACY | HCV | PREVALENCE | GASTROENTEROLOGY & HEPATOLOGY | Antiviral agents | Medical research | Safety and security measures | Medicine, Experimental | Hepatitis C virus | Hepatitis C | Drug therapy | Health aspects | Liver cirrhosis | Clinical trials | Chronic infection | Viruses | Infections | Patients | Cirrhosis | Hepatitis | Motivation | Interferon | Safety | Genotypes
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 9/2011, Volume 66, Issue 9, pp. 2092 - 2098
Journal Article
MMW - Fortschritte der Medizin, ISSN 1438-3276, 6/2019, Volume 161, Issue S2, pp. 38 - 42
Im vergangenen Jahr wurde die Leitlinie zur HIV-Postexpositionsprophylaxe überarbeitet. Sie gibt konkrete Empfehlungen, was nach Verdacht auf eine... 
Medicine & Public Health | HIV | antiretroviral therapy | General Practice / Family Medicine | Internal Medicine | AIDS | PEP | post-exposure prophylaxis
Journal Article
AIDS, ISSN 0269-9370, 07/1998, Volume 12, Issue 10, pp. 1149 - 1154
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2015, Volume 10, Issue 6, p. e0128069
Journal Article